CERITINIB-FORMULIERUNG

European patent · EP3148513 · In force

Register entry

Publication number
EP3148513
Application number
EP15727470
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 27, 2015
Published
Apr 5, 2017
Granted
Feb 26, 2020
Protection ends at the latest
May 26, 2035
Next annual fee due
May 31, 2027
IPC classes
A61K 9/20 (2006.01)
A61K 9/16 (2006.01)
A61K 31/435 (2006.01)
A61K 31/506 (2006.01)
Priority
US 201462004359 P 29.05.2014
PCT application
PCT/IB2015/053966 27.05.2015
PCT publication
WO2015/181739 03.12.2015
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  4. Jun 2, 2023

    Change

    Published in Swissreg on 02.06.2023

  5. Feb 26, 2020

    Granted

    Published in Swissreg on 26.02.2020

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

BREULLES, Sebastien

4002 Basel

ENSSLIN, Simon

4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.